Mumbai-based Healthtech startup develops India’s first universal genomic test for infectious disease

The test deploys Next-Generation Sequencing (NGS) technology to identify existing and emerging infections

The test deploys Next-Generation Sequencing (NGS) technology to identify existing and emerging infections
The test deploys Next-Generation Sequencing (NGS) technology to identify existing and emerging infections

HaystackAnalytics develops the first universal infectious disease genomic test

India’s first Universal Infectious Disease (ID) genomic test has been developed by Healthtech startup HaystackAnalytics, claiming to make it the world’s first company to bring genomics-based infectious diseases diagnostic to hospitals.

The Mumbai-based company is supported by the Department of Science & Technology, Government of India in addition to healthcare veterans like A Velumani, and private players such as GE Healthcare and Intel.

Gaurav Srivastava, co-founder, and COO of HaystackAnalytics said, “We are looking at a two-pronged approach. In the next two months, we start working with the top 10 to 15 hospitals in India. We are already building out a journey to expand the availability of this product to over 100 hospitals in the next six months and beyond. And, we are working with a couple of partners so that we are able to scale very fast.”

The test deploys Next-Generation Sequencing (NGS) technology to identify existing and emerging infections while providing information on drug resistance to support and identify correct treatment options for patients.

The company said the Universal ID test is a single test solution for the accurate and timely diagnosis of infectious diseases. The tests will be rolled out over the next three months in partnership with hospitals and diagnostic centers across the country, initially targeted at ICU patients in hospitals.

HaystackAnalytics has partnered with various diagnostic centers such as Unipath, Anderson, Sterling Accuris, Apollo Hospitals, and over 20 hospitals including AIIMS, to introduce their sequencing-based clinical products for TB and Covid in the past.

[With Inputs from IANS]

PGurus is now on Telegram. Click here to join our channel and stay updated with all the latest news and views

For all the latest updates, download PGurus App.

LEAVE A REPLY

Please enter your comment!
Please enter your name here